Corneal Collagen Cross-Linking

This policy covers epithelium-off corneal collagen cross-linking (riboflavin + UVA) for treatment of progressive keratoconus and corneal ectasia after refractive surgery in patients with documented progression (e.g., ≥1.0 D change in keratometry or astigmatism, or ≥0.50 D myopic shift). Coverage is limited to FDA‑approved epithelium‑off protocols using riboflavin 5′‑phosphate ophthalmic solutions (Photrexa/Photrexa Viscous) with the KXL System; epithelium‑on techniques and other indications are considered experimental/investigational, at least one year of clinical follow‑up is required, and the procedure is not universally curative with limited long‑term data.

"Progressive keratoconus"

Sign up to see full coverage criteria, indications, and limitations.